Function and application of Carabin in treatment of fatty liver and diabetes mellitus type 2

A technology for diabetes and fatty liver, applied in the fields of medical preparations containing active ingredients, metabolic diseases, screening of compounds, etc., can solve the problems of lack of clinical trial support, etc., and achieve the effect of inhibiting fatty liver and type II diabetes.

Active Publication Date: 2017-05-31
武汉惠康达科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of the data come from preclinical

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Function and application of Carabin in treatment of fatty liver and diabetes mellitus type 2
  • Function and application of Carabin in treatment of fatty liver and diabetes mellitus type 2
  • Function and application of Carabin in treatment of fatty liver and diabetes mellitus type 2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] [Example 1] Obtaining mouse fatty liver and type 2 diabetes model (diet induced obesity, DIO)

[0037] (1) Grouping of experimental animals: 8-week-old, male, Alb-cre mice and Carabin-KO mice were selected and given two special feeds, D12942 high-fat diet (High fat diet, HFD) and D12450B low-fat diet ( Normal chow, NC) feeding, that is, Alb-cre NC group, Carabin-KO NC group, Alb-cre HFD group, Carabin-KO HFD group, a total of 4 groups.

[0038] (2) The model induces the operation process through high-fat feed:

[0039] Alb-cre and Carabin-KO mice were used to establish DIO models, and phenotype correlation analysis was performed to clarify the role of Carabin gene in fatty liver and type Ⅱ diabetes. Eight-week-old, male, Alb-cre mice and Carabin-KO mice were selected and fed with two special diets, D12942 high fat diet (High fat diet, HFD) and D12450B low fat diet (Normalchow, NC), respectively, namely Alb-cre NC group, Carabin-KO NC group, Alb-cre HFD group, and Cara...

Embodiment 2

[0040] [Example 2] Determination of mouse body weight and blood sugar level

[0041] (1) Detection of fasting body weight of mice

[0042] ①Fasting: fast the mice to be tested at 8:00 am (without water), and start the experimental operation at 2:00 pm.

[0043] ② Weighing: Weigh at 0 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks respectively. In a small bucket, measure the weight and record the data.

[0044] (2) Fasting blood glucose level detection experiment

[0045] All the mice to be tested were fasted from 8:00 am to 2:00 pm (without water), that is, the experimental operation was started after 6 hours of fasting.

[0046] ① Blood glucose meter preparation: Check the battery of the blood glucose meter (Johnson & Johnson, ONETOUCH), press the right switch, put the test strip into the left slot correctly, the screen will display the code corresponding to the blood glucose test strip, and then display the dripping blood pattern, Indicates that the blo...

Embodiment 3

[0051][Example 3] Glucose tolerance test (intraperitoneal glucose tolerance test, IPGTT)

[0052] On the 10th week of the experiment, the intraperitoneal injection of glucose test (IPGTT) was performed to evaluate the glucose tolerance of the mice.

[0053] (1) Before measuring blood glucose, measure the fasting body weight of the mice, and calculate the injection volume of glucose based on 10 μL / g.

[0054] (2) First detect the fasting blood glucose level at 0 minutes before the glucose injection, and inject the glucose solution intraperitoneally quickly after the detection is completed.

[0055] (3) Operation method of intraperitoneal injection: ①Fix the mouse; grab the mouse, grab the tail of the mouse with the little finger and ring finger of the left hand, and grab the neck of the mouse with the other three fingers, so that the head of the mouse is downward, and the The abdomen of the mouse is fully exposed. ②Needle positioning and injection: Insert the needle from the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a function and an application of Carabin (Cara) in treatment of fatty liver and diabetes mellitus. An Alb-cre (cre) mouse and a Cara hepatocyte-specific gene knockout (Cara-KO) mouse are taken as experimental subjects, on the basis of a high fat diet induced obesity mouse model and compared with the cre mouse, the Cara-KO mouse shows obesity, the fasting blood-glucose level of the Cara-KO mouse is obviously higher than that of the cre mouse, and IPGTT (intraperitoneal glucose tolerance test) discovers that the glucose tolerance capacity of the Cara-KO mouse is weakened obviously. Liver weight, liver/weight ratio, pathological staining results and the like all prove that fatty liver lesions of the high fat diet induced Cara-KO mouse are more serious, and lipid accumulation is increased remarkably. Cara can be taken as a target for screening fatty liver and/or diabetes mellitus type 2 treating drugs, and a Cara accelerator can be used for preparing fatty liver and/or diabetes mellitus type 2 treating drugs.

Description

technical field [0001] The invention belongs to the field of gene function and application, and particularly relates to the application of Carabin (also known as TBC1D10C or Carabin) as a target gene in the preparation of drugs for preventing, alleviating and / or treating fatty liver and / or type II diabetes. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD, nonalcoholic fatty liver disease) is caused by a group of factors other than alcohol and other clear liver damage. ) as the main feature of the metabolic syndrome. Surveys show that the incidence of NAFLD in non-obese people is 10% to 20%, and at 25kg / m 2 <body mass index (BMI, body mass index)<30kg / m 2 About 63.4% of the population, and in the BMI> 30kg / m 2 The population is about 89.1%, and the incidence of NAFLD in patients with type Ⅱ diabetes is about 50% [1]. The incidence of NAFLD in children is also increasing, approximately 3%, and may increase with age [2]. Studies have shown th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68G01N33/68A61K45/00A61P1/16A61P3/10
CPCA61K45/00C12Q1/6883C12Q2600/136C12Q2600/158G01N33/6893G01N2500/04
Inventor 李红良魏翔方静
Owner 武汉惠康达科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap